First-Line Brivanib Fails Against Sorafenib on OS End Point in HCC

Share this content:
(ChemotherapyAdvisor) – A randomized phase 3 trial comparing first-line treatment with the investigational compound brivanib vs sorafenib in patients with advanced hepatocellular carcinoma did not meet its primary overall survival end point based on a noninferiority statistical design, Bristol-Myers Squibb Company reported.

The double-blind BRISK-FL study randomized patients in 179 centers worldwide to oral brivanib 800mg/day and oral placebo twice daily or oral sorafenib 800mg twice daily and oral placebo once daily. Estimated enrollment was 1,050 patients.

Brivanib is an investigational, oral, anti-tumorigenic that inhibits vascular endothelial growth factor receptor and fibroblast growth factor receptors.

Bristol-Myers Squibb noted it has shared BRISK-FL results with the clinical trial investigators and will work with them in the ongoing management of patients still receiving the study drug. Results of BRISK-FL will be reported at a future scientific meeting.

Press Release Listing

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs